PRAMOMOLECULAR

PRAMOMOLECULAR is a pioneering force in biotechnology research, dedicated to silencing severe diseases affecting the lung and pancreas. With a focus on developing self-delivering siRNAs, PRAMOMOLECULAR is creating therapeutic oligonucleotides that can effectively downregulate mRNAs in vital organs, including the lung, pancreas, heart, and colon. This innovative approach is geared towards developing drug candidates that can causally cure serious cancers such as lung, colon, or pancreatic carcinoma, as well as metabolic diseases like Noonan syndrome.

The company's unique technology involves coupling defined lipid residues directly to siRNAs via defined chemical bonds, resulting in a patent-protected platform that facilitates the introduction of therapeutic oligonucleotides into organs beyond the liver. This advancement holds significant therapeutic importance, as siRNA delivery has traditionally been limited to local applications or systemic delivery in the liver. PRAMOMOLECULAR is committed to providing siRNA-based drug candidates for various other organs, expanding the scope of potential treatments.

PRAMOMOLECULAR operates from its primary location at Zeitzer Str. 94, Gera, 07552, DE, and also maintains a presence at Gustav-Meyer-Allee 25, Technische Universität Berlin, Berlin, 13355, DE. The company is dedicated to providing disease-specific drug candidates to address overexpressed or mutated RAS proteins, which can lead to severe metabolic diseases or cancer. PRAMOMOLECULAR is initially targeting KRAS-dependent cancers, including non-small cell lung cancer, pancreatic adenocarcinoma, and melanoma.

We invite the manager of PRAMOMOLECULAR to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial success.